Document is current
Any future updates will be listed below
-
Authors
Davis, Kaitlyn E.
Kana, Rajesh K.
Szaflarski, Jerzy P.
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke Training Program in Neurobiology of Cognition and Cognitive Disorders T32 (NS061788)
- License Information
-
More Information
Article History
Accepted: 17 June 2025
First Online: 28 June 2025
Declarations
:
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: K.D. and R.K. have no competing interest. J.S. discloses the following: Funding: NIH, NSF, DoD, Shor Foundation for Epilepsy Research, UCB Biosciences, NeuroPace Inc., SAGE Therapeutics Inc., Serina Therapeutics Inc., LivaNova Inc., Greenwich Biosciences Inc., Biogen Inc., Eisai Inc., State of AL Consulting/Advisory Boards: PureTech Health, Biopharmaceutical Research Company, LivaNova Inc., UCB Pharma, AdCel Pharma, iFovea Inc. Editor-in-Chief, Epilepsy & Behavior Reports (paid) Editorial board member for Epilepsy & Behavior, Journal of Epileptology (associate editor), Journal of Medical Science, and Folia Medica Copernicana. Dr. Szaflarski has served on the Alabama Medical Cannabis Commission (2021–2024; nominated by Dr. Scott Harris, State Health Officer).
